Milatuzumab is a humanized monoclonal antibody that targets CD74. Milatuzumab reduced proliferation, alterations in migration, and adhesion molecule expression preferentially of CD27- na?ve B cells. Milatuzumab is used for the treatment of multiple myeloma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia.